HOME >> BIOLOGY >> NEWS
Cost-effectiveness of treating multidrug-resistant tuberculosis

Researchers have made predictions as to how the tuberculosis (TB) epidemic in Peru might progress over the next 30 years, depending on what measures are used to fight it. They considered the five different approaches to treating drug-resistant TB that are open to the Peruvian health authorities.

TB is a growing problem worldwide. Most cases can be treated effectively with a standard treatment (known as 'DOTS', which stands for 'Directly Observed Therapy Short-Course') but an increasing number of cases are resistant to all the various 'first-line' treatment drugs; this is known as multi-drug resistant (MDR) TB. MDR-TB must be treated with 'second-line' drugs. There are several different options; for example, doctors could give second-line drugs whenever a first attempt at treatment has failed, or only use these drugs in cases where tests have confirmed MDR-TB to be the problem. MDR-TB cases could all be given the same standard treatment or, based on tests, each could have 'individualized' treatment.

The researchers used a method called 'modelling'. They performed calculations based on information already available about TB in Peru, where there are 120 new TB infections per 100,000 people every year and 4.5% of existing cases have MDR-TB. They concluded that use of second-line drugs would be cost-effective for Peru and that, despite the extra costs of individualized treatment, this is the best option. The results will be of interest in other developing countries. The researchers say, "In other settings, the attractiveness of strategies using second-line drugs will depend on TB incidence, MDR burden, and the available budget, but simulation results suggest that individualized regimens would be cost-effective in a wide range of situations". They also stress it is important for the standard first-line DOTS treatment to be made widely available.


'"/>

Contact: Andrew Hyde
ahyde@plos.org
44-122-346-3330
Public Library of Science
3-Jul-2006


Page: 1

Related biology news :

1. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
2. Brain blood flow gives clues to treating depression
3. New strategy for treating allergic disorders
4. Developer of new method for treating bone defects wins WPI Entrepreneurship Award
5. UCF nanoparticle offers promise for treating glaucoma
6. Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer
7. 8 plants from South Africa may hold potential for treating high blood pressure
8. Arctic ice retreating more quickly than computer models project
9. Nanotechnology offers hope for treating spinal cord injuries, diabetes and Parkinsons disease
10. Discovery in plants suggests entirely new approach to treating human cancers
11. Preventing and treating lung cancer -- ESMO explores collaboration to fight cancer on all fronts

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2020)... ... ... Toronto-based clinical research organization (CRO) and regulatory consulting firm, dicentra , has announced ... Clarksburg on a farm on Beaver Valley Road. , The owners currently operate an ... it would be a great new option for employees to relocate to. , “Part ...
(Date:3/2/2020)... CHICAGO (PRWEB) , ... March 02, 2020 , ... ... attendance at the 71st annual Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy ... in Chicago, Illinois. Pittcon is the world’s leading annual conference and exposition on ...
(Date:2/28/2020)... ... February 27, 2020 , ... An upcoming episode of Advancements ... maladies, such as Inflammatory Bowel Disease (IBD), specifically Crohn’s Disease (Crohn’s), and Oncology. ... a novel platform developed by Deka Biosciences, Inc. (Deka Biosciences), that will enable ...
Breaking Biology News(10 mins):
(Date:3/19/2020)... ... March 17, 2020 , ... ... with pioneering gene circuit company Senti Biosciences, Inc. (Senti) to accelerate the ... solid tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell ...
(Date:3/10/2020)... ... March 10, 2020 , ... Ortho Clinical Diagnostics, a global leader of ... its ORTHOTM Sera, ID-MTS, a suite of extended antigen in a gel testing format ... on ORTHO VISION® and ORTHO VISION® Max in the United States and Canada. The ...
(Date:3/4/2020)... ... March 04, 2020 , ... This month, Cognosante will ... FL. The company will showcase both expanded and emerging offerings that align with the ... is designed to be comprehensive, timely, and engaging. From Interoperability and ...
(Date:2/28/2020)... ... February 26, 2020 , ... Designed primarily for laboratory and ... dedicated controller, thus simplifying setup, streamlining integration, and optimizing workflow. Capable of recording ... Fastec Imaging’s new HS Series cameras to be released. The HS Series includes ...
Breaking Biology Technology:
Cached News: